ياد يي

O 1 P & 6

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO. 0459-0554P APPLICATION NO. 09/781,893

APPLICANT

Kent JORGENSEN, et al.

FILING DATE

GROUP

February 9, 2001 Unassigned

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER				ER		DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
1/4	5	8	2	7	8	3	6	1998-10-27	Peterson, et al.			
	5	4	8	4	9	1	1	1996-01-16	Hong, et al.			
	4	6	2	2	3	9	2	1986-11-11	Hong, et al.			
	5	9	4	2	2	4	6	1999-08-24	Mayhew, et al.			
	5	9	3	2	2	4	2	1999-08-03	Franklin, et al.			
	5	9	6	5	1	5	9	1999-10-12	Mayhew, et al.			
	6	0	0	7	8	3	9	1999-12-28	Mayhew, et al.			
	5	8	8	2	6	7	9	1999-03-16	Needham			
	5	9	8	5	8	5	4	1999-11-16	Kozak			
	6	0	7	7	8	3	7	2000-06-20	Kozak			
	6	1	3	6	7	9	6	2000-10-24	Kozak			
 	6	1	6	6	0	8	9	2000-12-26	Kozak			

FOREIGN PATENT DOCUMENTS PANSLATION COUNTRY SUB DOCUMENT NUMBER DATE SPAIN 1994-03-01 84 0 3 8 M PCT 1994-04-28 0 1 WO 94 0 9 PCT 1994-10-13 8 WO 94 2 4 2 PCT 1999-01-21 0 WO 99 1 PCT 1999-01-21 8 5 WO 99 1999-04-08 PCT WO 99 6 1

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

4	"Therapeutic Activity of a Thioether-Lipid Conjugate of $1-\beta$ -D-Arabino-furanosylcytosine in Human Colorectal Cancer Xenografts", R. Herrmann, et al, Am. Assoc. Cancer Res., Vol. 52, No. 7, pp. 1865-1867 (1992)
	"Competitive Inhibition of Lipolytic Enzymes. IX. A comparative Study on the Inhibition of Pancreatic Phospholipases A ₂ from Different Sources by (R)-2-acylamino Phospholipid Analogues", G. H. de Haas, et al, BBA - Lipids and Lipid Metabolism, NL, Elsevier Science BV., Vol. 1167, No. 3, 1993, pp. 281-288
\	"The Chemical Synthesis of a Series of Ether Phospholipids From D-Mannitol and Their Properties", J Xia, et al, Tetrahedron: Asymmetry, Vol. 8, No. 18, pp. 3131-3142, 1997
1. 1	

EXAMINER

DATE CONSIDERED

8/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

ATTY DOCKET NO. 0459-0554P APPLICATION NO. 09/781,893

INFORMATION DISCLOSURE

(light reviews) where is account.		Kent JORGENSEN, et al.									
(Use several sheets if necessary)		February 9, 200	Unassigned								
Ŭ.S.	PATENT D	OCUMENTS		-		-					
XAMINER DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE						
				<u> </u>							
FOREI	GN PATENT	DOCUMENTS				-					
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS	LATION					
		<u></u>			YES	NO					
- - - - - - - -											
HER DOCUMENTS											
HER DOCUMENTS (Include Name of the author (in nal, serial, symposium, catalog, etc.) date, page(s), volume-in	CAPITAL LETTERS), tit ssue number(s), publi	le of the article (when appropris sher, city and/or country where p	te), title ublished.	of the item	(book, ma	gasine,					
Analogs in Human Leukemi Fibroblasts", D. Hoffman	"Cytotoxicity of Platelet Activating Factor and Related Alkyl-Phospholipid Analogs in Human Leukemia Cells, Polymorphonuclear Neutrophils, and Skin Fibroblasts", D. Hoffman, et al, Blood, Vol. 63, No. 3, 1984, pp. 545-552										
Delivery", J. Davidsen,	Enzymatic Degradation of Polymer Covered SOPC-Liposomes in Relation to Drug Delivery", J. Davidsen, et al, Symposium on Lipid and Surfactant Self-Assemblies: Structure, Dynamics and Reactions, Feb. 24-25, 2000, Uppsala, Sweden										
"Controlled Destabilizat A ₂ ", J Davidsen, et al, 1	"Controlled Destabilization of Liposomal Drug Delivery Systems by Phosp A_2 ", J Davidsen, et al, Dec. 1999										
octadecyl-2-0-methyl-sn-	"Increased Cell-surface Receptor Expression on U-937 Cells Induced by 1-0-octadecyl-2-0-methyl-sn-glycero-3-phosphocholine", M. Pushkareva, et al, Cancer Immunol Immunother (2000) 48: 569-578										
"Ether Lipids in the The Pharmacol, Vol 22, pp. 1	"Ether Lipids in the Therapy of Cancer", R. Andreesen, Prog. Biochem, Pharmacol, Vol 22, pp. 118-131 1988										
"1-β-D-Arabinofuranosylc C. Hong, et al, Cancer D	"1- β -D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C", C. Hong, et al, Cancer Drug Delivery, Vol. 1, No. 3, 1984, pp. 181-190										
Arabinofuranosylcytosine	"Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1- β -D-Arabinofuranosylcytosine Conjugates of Ether Lipids", C. Hong, et al, J. Med. Chem. 1986, 29, 2038-2044										
"Phospholipid Antitumor Reviews, Vol. 15, No. 3,	"Phospholipid Antitumor Agents", W. Houlihan, et al., Medicinal Research Reviews, Vol. 15, No. 3, 157-223 (1995)										
"Antitumor Ether Lipids the Future, 1994, 19(11)	"Antitumor Ether Lipids and Alkylphosphocholines", M. Lohmeyer, et al, Drugs of the Future, 1994, 19(11): 1021-1037										
et al, British Journal o	"Growth Arrest vs. Direct Cytotoxicity and the Importance of Molecular Structure for the In vitro Anti-Tumor Activity of Ether Lipids", M. Lohmeyer, et al, British Journal of Cancer (1995) 72, pp. 277-286										
Liposomes: Effects of Liposomes, et al., Pharma	"Enhancement of Phospholiphase A2 Catalyzed Degradation of Polymer Grafted PEG- Liposomes: Effects of Lipopolymer-concentration and Chain-Length", K Jorgensen, et al., Pharmaceutical Research, Vol. 16, No. 9, 1999 pp. 1491-1493										
"Increase in Phospholipas Liposomes, C. Vermehren,	se A_2 Activit et al, BBA,	y Towards Lipopolym 1998, pp.27-36	er-Con	taining	T T						
NER: Initial if citation considered, whether or not citation is dered. Include conv. of this form with next communication to a		DATE CONSIDERED 8/0	L								